Lebrikizumab

Drug Profile

Lebrikizumab

Alternative Names: MILR1444A; MILR1444Ab; RG-3637; RO-5490255; TNX-650

Latest Information Update: 15 Jun 2017

Price : $50

At a glance

  • Originator Tanox
  • Developer Chugai Pharmaceutical; Comprehensive Clinical Research Network; Genentech; Roche; Tanox
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Idiopathic pulmonary fibrosis
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Hodgkin's disease

Most Recent Events

  • 27 Apr 2017 Discontinued - Phase-II for Chronic obstructive pulmonary disease (Adjunctive treatment) in USA, Bulgaria, Canada, Denmark, Hungary, Poland, Russia, Argentina, Argentina, Mexico (SC) because it did not meet the primary endpoint of a phase II trial (Roche pipeline, April 2017)
  • 16 Mar 2017 Discontinued - Phase-III for Asthma (Adjunctive treatment, In adolescents) in USA, Germany, Portugal, Hungary, Italy, Czech Republic, Spain, Poland, Argentina, Canada, Colombia, France, South Korea, South Korea, Israel, Mexico, Peru, Slovakia, South Africa, Taiwan, Brazil, Japan, Ukraine, United Kingdom (SC) (Roche email communication, March 2017)
  • 01 Feb 2017 Roche completes a phase II trial in Chronic obstructive pulmonary disease (Adjunctive treatment) in USA, Argentina, Bulgaria, Canada, Denmark, Hungary, Mexico, Poland and Russia (NCT02546700)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top